MorphoSys Appoints Head of Clinical Development
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ MorphoSys Fills Key Position in Expanding Proprietary DevelopmentTeamMorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announcedtoday the appointment of Lisa Rojkjaer, MD, as Vice President andHead of Clinical Development. Dr. Rojkjaer joins MorphoSys fromNovartis Pharma AG where she most recently held the position of Headof Medical Affairs - Hematology, Europe, following her appointment asglobal clinical program head for Exjade®. Here she was responsiblefor all clinical activities in Europe for Novartis's Hematologyportfolio including Gleevec® and Exjade®. Prior to her tenure atNovartis, she spent five years with Novo Nordisk, in Copenhagen,Denmark, and Princeton, USA as the Director of Global Medical AffairsBiopharmaceuticals and later Director, Clinical DevelopmentHematology. During her time with Novo Nordisk she established aglobal medical affairs group for biopharmaceuticals and headed theclinical development of the US hematology portfolio amongst otheraccomplishments. Dr. Rojkjaer is a board certified hematologist andreceived her MD degree from the University of Toronto, where she alsodid her residency in internal medicine and fellowship in hematology. She has held academic and hospital appointments in the US, Canadaand Europe."We are committed to building an excellent development organizationby hiring top talent. Thus, I am particularly delighted to welcomeLisa Rojkjaer to occupy a key position in our growing developmentteam," commented Dr. Arndt Schottelius, Chief Development Officer ofMorphoSys AG. "Lisa brings extensive experience of drug developmentin the pharmaceutical industry, which will support us in our plans toadvance and expand our proprietary pipeline and to develop a constantflow of valuable drug candidates."MorphoSys's expanding proprietary product development activities arefunded by cash-flows from its partnered discovery business. MorphoSys plans to significantly broaden its proprietary therapeuticantibody pipeline in 2009 and the years ahead. At the end of 2009,the company expects a total of up to eight proprietary antibodyprograms ongoing, with its lead development program MOR103 in a phase2 clinical trial and seven programs in preclinical development anddiscovery stage."I'm looking forward to working with the entire R&D team at MorphoSysto execute the Company's strategy and move antibody programs throughclinical trials quickly and efficiently. Through both my academicand medical careers as well as my time within the pharmaceuticalindustry I gained profound scientific and drug development knowledgein hematology and oncology, which I will apply to advance MorphoSys'sgrowing clinical pipeline," commented Dr. Rojkjaer.About MorphoSys:MorphoSys is an independent biotechnology company that develops novelantibodies for therapeutic, diagnostic and research applications. TheCompany's HuCAL technology is one of the most powerful methodsavailable for generating fully human antibodies. By successfullyapplying this and other proprietary technologies, MorphoSys hasbecome a leader in the field of therapeutic antibodies, one of thefastest-growing drug classes in human health-care. Through itsalliances with some of the world's leading pharmaceutical companies,MorphoSys has created a pipeline of more than 60 drug candidates. TheCompany is expanding its drug pipeline by adding new partneredprograms, and by building a portfolio of fully-owned therapeuticantibodies. For its proprietary portfolio, the Company is focused onthe areas of oncology and inflammation, within which it plans to haveeight active programs by the end of 2009. Its most advanced programis MOR103, a first-in-class, fully human antibody against GM-CSF.MorphoSys expects to commence a Phase Ib/IIa trial of this antibodyin rheumatoid arthritis patients in the second half of 2009. Via itsbusiness unit AbD Serotec, MorphoSys is expanding the reach of itstechnologies in the diagnostics and research markets. MorphoSys isheadquartered in Munich, Germany and listed on the Frankfurt StockExchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® areregistered trademarks of MorphoSys AG.This communication contains certain forward-looking statementsconcerning the MorphoSys group of companies. The forward-lookingstatements contained herein represent the judgment of MorphoSys as ofthe date of this release and involve risks and uncertainties. Shouldactual conditions differ from the Company's assumptions, actualresults and actions may differ from those anticipated. MorphoSys doesnot intend to update any of these forward-looking statements as faras the wording of the relevant press release is concerned.For more information, please contact MorphoSys:Dr. Claudia Gutjahr-LöserHead of Corporate Communications & IRTel: +49 (0) 89 / 899 27-122gutjahr-loeser(at)morphosys.comMario BrkuljSenior Manager Corporate Communications & IRTel: +49 (0) 89 / 899 27-454brkulj(at)morphosys.comJessica KulpiSpecialist Corporate Communications & IRTel: +49 (0) 89 / 899 27-454kulpi(at)morphosys.comhttp://hugin.info/130295/R/1341324/320800.pdf --- End of Message ---MorphoSys AGLena-Christ-Str. 48 Martinsried / München GermanyWKN: 663200; ISIN: DE0006632003; Index: CDAX, HDAX, Prime All Share, TECH All Share, TecDAX, MIDCAP;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 16.09.2009 - 07:30 Uhr
Sprache: Deutsch
News-ID 5846
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 361 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Appoints Head of Clinical Development"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
